CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) Short Interest Update

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 10,800 shares, a growth of 33.3% from the March 15th total of 8,100 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is presently 1.3 days.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Friday, April 5th.

CollPlant Biotechnologies Stock Up 0.4 %

Shares of NASDAQ CLGN opened at $5.24 on Monday. The stock has a market capitalization of $60.00 million, a price-to-earnings ratio of -8.20 and a beta of 0.24. The stock’s fifty day simple moving average is $5.30 and its 200 day simple moving average is $5.44. CollPlant Biotechnologies has a 52-week low of $4.22 and a 52-week high of $8.90.

Hedge Funds Weigh In On CollPlant Biotechnologies

A number of hedge funds have recently modified their holdings of CLGN. Villere ST Denis J & Co. LLC grew its holdings in shares of CollPlant Biotechnologies by 20.4% in the 4th quarter. Villere ST Denis J & Co. LLC now owns 361,293 shares of the company’s stock worth $2,309,000 after acquiring an additional 61,120 shares during the last quarter. LPL Financial LLC purchased a new position in shares of CollPlant Biotechnologies during the second quarter valued at $361,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CollPlant Biotechnologies during the second quarter valued at $189,000. Jane Street Group LLC purchased a new position in shares of CollPlant Biotechnologies during the third quarter valued at $90,000. Finally, Credit Suisse AG purchased a new position in shares of CollPlant Biotechnologies during the fourth quarter valued at $51,000. 21.69% of the stock is currently owned by institutional investors and hedge funds.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.